To compare the levodopa/carbidopa (LC) and levodopa/benserazide (LB) pharmacokinetic profiles following repeated doses of opicapone (OPC) administered apart from levodopa.
Introduction
Despite decades of clinical use, levodopa still remains the most effective symptomatic treatment in Parkinson's disease [3] [4] [5] [6] . The therapeutic effect of levodopa depends on its biotransformation to dopamine in the brain. However, levodopa undergoes rapid and extensive metabolism by peripheral aromatic L-amino acid decarboxylase (AADC) and catechol-Omethyltransferase (COMT) and only 1% of an oral dose of levodopa actually reaches the brain [7, 8] . Therefore, levodopa is usually coadministered with an AADC inhibitor (AADCi, either carbidopa or benserazide), which increases levodopa bioavailability. However, when using levodopa combined with an AADCi approximately 90% of a levodopa dose undergoes conversion by COMT to 3-O-methyldopa, which competes with levodopa at the level of the bloodbrain barrier for transport [9] [10] [11] [12] . Thus, an additional strategy to further prevent the peripheral levodopa metabolism and increase the delivery of levodopa to the brain is based on the administration of a COMT inhibitor [13] [14] [15] . Only two COMT inhibitors (tolcapone and entacapone) are currently available for clinical use, and both have some clinical limitations. Tolcapone requires liver function monitoring and thus is limited to fluctuating patients poorly controlled with other therapies [16] . Entacapone is considered to be safe [17] , but its efficacy is limited and requires frequent dosing [7] . Therefore, there is a need for more efficacious and safer COMT inhibitors.
Opicapone ( Parkinson's disease patients. OPC was designed as a hydrophilic 1,2,4-oxadiazole analogue with a pyridine N-oxide residue at position 3, providing high COMT inhibitory potency and avoiding cell toxicity [18, 19] . OPC is endowed with an exceptionally high binding affinity (subpicomolar K d ) [20] that translates into a slow complex dissociation rate constant and a long duration of action in vivo [21] . In liver and brain homogenates from rats administered with OPC, tolcapone and entacapone by gastric tube, OPC showed a stronger and more sustained COMT inhibitory effect than tolcapone and entacapone. One h after administration, COMT inhibition was 99% with OPC vs. 82% with tolcapone and 68% with entacapone. Nine hours after administration, entacapone showed no COMT inhibition and tolcapone produced minimal inhibitory effect (16%), whereas OPC continued to inhibit COMT activity by 91% [21, 22] .
In an entry-into-man study in healthy male volunteers, single doses of OPC ranging from 10 to 1200 mg were well tolerated. The adverse event (AE) profile did not differ from that of placebo and the clinical safety tests showed no sign of concern. The extent of systemic exposure to OPC increased in an approximately dose-proportional manner and, despite the short half-life (t 1/2 : 0.8-3.2 h), a dose-dependent and long-lasting COMT inhibitory effect was observed with a maximum S-COMT inhibition (E max ) ranging from 34.5% (10 mg) to 100% (1200 mg), and an inhibition of 25.1-76.5% remained 24 h postdose [23, 24] . Following an 8-day once-daily multiple-dose regimen up to 30 mg OPC, sulfated OPC was the predominant metabolite and the bile is likely to be the main route of OPC excretion [24] . Maximum S-COMT inhibition (E max ) ranged from 69.9% to 98.0% following the last dose of OPC [24] . A study in healthy subjects that compared the levodopa pharmacokinetic (PK) profile throughout a day driven by the COMT inhibition either following repeated doses of OPC or concomitant administration with entacapone, demonstrated superiority of OPC over entacapone upon the bioavailability of levodopa in association with more pronounced, long-lasting, and sustained COMT inhibition [25] . Studies in healthy subjects with concomitant administration of OPC and levodopa/AADCi (either carbidopa or benserazide) demonstrated that OPC was well tolerated, inhibited the COMT in a potent manner, but showed a certain degree of interaction during the absorption phase between levodopa/AADCi and OPC (data on file), which was considered to be minimized by separating 1 h both administrations. A phase IIa exploratory pilot study in Parkinson's disease patients with motor fluctuations showed that 30 and 15 mg OPC inhibited COMT activity, increased the levodopa bioavailability, and significantly improved various motor outcomes, including a dose-dependent change in absolute OFF-time, and was well tolerated when administered with standard release 100/25 mg levodopa/carbidopa or levodopa/benserazide [26] . The efficacy and safety profile of OPC based on pooled efficacy data from two pivotal, multinational, double-blind, randomized, parallel-group, 14-week, placebo-and activecontrolled studies in patients with Parkinson's disease and motor fluctuations, including a total of 758 patients (placebo n = 255,OPC 25 mg n = 241, OPC 50 mg n = 262) has been recently presented [27, 28] . OPC (50 mg) provided a mean reduction in OFF-time of 60.8 min vs. placebo as an adjunct to levodopa in patients with Parkinson's disease with endof-dose motor fluctuations and is, therefore, the only oncedaily COMT inhibitor to provide a mean reduction in time in the OFF state that is clinically relevant [29] . In addition, a higher proportion of patients in the OPC 50 mg group than in the entacapone group had improved on both the clinician's and patient's global impression of change [29] .
OPC was well tolerated in studies in several animal species (data on file; BIAL -Portela & Cª, S.A.), healthy volunteers [23, 25, [30] [31] [32] and Parkinson's disease patients [27] [28] [29] 33] .
The present studies aimed to investigate the effect of repeated, once-daily, OPC doses upon COMT activity and levodopa PK using a regimen in which OPC and levodopa/AADCi administrations were separated by at least 1 h and, additionally, foreseeing that daily therapeutic regimens of levodopa could be enhanced and better optimized with an OPC oncedaily evening regimen.
Methods

Study designs
We conducted two randomized, double-blind, sex-balanced and placebo-controlled studies. The first study (Study 1; trial registration NCT01533116) was a single centre (Algorithme Pharma Inc., Quebec, Canada) phase 1 study, in four groups of 12 healthy subjects each (six male and six female) who received a once-daily morning administration of OPC ( On each dosing day, subjects were fasting from all food for a minimum of 4 h (8 h for Study 1) before dosing and remained fasted until at least 2 h (4 h for Study 1) postdose. On LC and LB dosing days, subjects had an overnight fast for at least 8 h before the levodopa administration and remained fasted until at least 3 h post-dose. Water drinking was allowed as desired except for 1 h before and after each dosing.
At least from 48 h before the first dosing and during the treatment period, subjects were requested to abstain from smoking, drinking alcohol, coffee, tea or beverages containing xanthines. The consumption of food or beverages containing grapefruit was not allowed starting from one week before dosing until end of clinical phase.
The Sample size estimation was based on a primary levodopa parameter (AUC 0-∞ ). In a previous study [34] a within-subject variability (CV%) of 27.5% was observed for levodopa AUC 0-∞ . Assuming an alpha error of 5% (two-tailed) and a within-subject CV of 27.5%, 48 subjects (12 subjects per treatment group) provided 80% probability (power) to detect a 30% difference in the geometric means of levodopa AUC 0-∞ . In Study 2, 72 subjects (18 subjects per treatment group) were to be enrolled. The comparison between treatment arms was done according to the bioequivalence reference interval of 80-125%. The reference interval (bioequivalence testing), although extensively used for PK evaluations within the compound and/or formulations, was used in the present study for evaluation between treatment arms, even different, but with related endpoints, i.e., PK and pharmacodynamics (PD).
Subjects who withdrew or dropped-out from the study had to be replaced to allow the completion of the necessary subjects. The replacement subject was assigned to the same treatment group as the replaced subject.
Both studies were conducted according to the Helsinki Declaration, ICH Good Clinical Practice recommendations and applicable local regulations. Study 1 was approved by an Independent Ethics Committee (ETHIPRO, Comité d'Éthique de la Recherché Independent, Canada) and by the Canadian Agency (Health Canada -Therapeutic Products Directorate). Study 2 was approved by an Independent Ethics Committee (CPP -Comité de Protection des Personnes, Ouest VI, Brest, France) and by the French Medicines Agency (ANSM, formerly AFSSAPS). Written informed consent was obtained from each study participant.
Safety assessments
Safety and tolerability assessments included routine laboratory tests (blood chemistries, haematological profile, coagulation and urinalysis), physical examination, ECG, and vital signs. Any undesirable sign, symptom, or medical condition occurring after starting the study, whether reported spontaneously or when prompted, was recorded regardless of suspected relation to the study medication.
Blood sampling for PK and PD assays
Blood samples (3 ml for Study 1 and 6 ml for Study 2) for PK analyses of OPC were drawn by direct venipuncture or intravenous catheter into potassium ethylenediaminetetraacetic acid tubes, at the following time points on each LC or LB dosing days: pre-LC/LB dose and then at 0.5, 1, 1. ) . After collection, blood samples were centrifuged at approximately 1500 g for 10 min at 4°C, and the resulting plasma was then separated into two aliquots of 0.5 ml which were stored at À70°C until required for analysis.
Blood samples (3-ml) for PK analyses of levodopa and 3-Omethyldopa (3-OMD) were drawn by direct venipuncture or intravenous catheter into potassium ethylenediaminetetraacetic acid tubes, at the following time points on each LC or LB dosing days: pre-LC/LB dose and then at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 (Study 1 only) and 24 (Study 1 only) h post-LC/LB dose.
After collection, blood samples were centrifuged at approximately 1500 g for 10 min at 4°C, and the resulting plasma was then separated into two aliquots of 0.5 ml which were stored at À70°C until required for analysis.
Blood samples collected for OPC PK assays served for the PD assessments. After centrifugation and removal of plasma, the supernatant (uppermost erythrocyte layer) was removed and the tubes containing the erythrocytes were placed in ice. Then, a volume of cold 0.9% NaCl solution equal to double that of erythrocytes was added. The erythrocytes were centrifuged (at 4°C and approximately 1500 g for 10 min) and the washing procedure was repeated three times. Then, two aliquots accurately pipetted of 0.5 ml washed erythrocytes were prepared and stored at À70°C until required for analysis.
S-COMTassay
Determination of S-COMT activity was carried out in compliance with good laboratory practice (GLP) at BIAL's Pharmacological Laboratory (S. Mamede do Coronado, Portugal) according to a validated method [23, 24] . In brief, prewashed erythrocytes samples were haemolyzed with three volumes of ice-cold water. After vortexing, the samples were left standing on ice for 10 min and then centrifuged for 20 min at 2-8°C at 20 000 g. The supernatant was used for S-COMT assay, which was carried out immediately after sample preparation. The incubation mixture contained 300 μl enzyme preparation, 375 μ incubation medium and 75 μl of 5 mmol l -1 adrenaline as S-COMT substrate. The samples were incubated in a water bath at 37°C for 60 min. The tubes were transferred to ice and the reaction was stopped by adding 75 μl of ice-cold 4 mol l -1 perchloric acid. The samples were incubated in a refrigerator at 2-8°C for 2 h and then centrifuged at 2-8°C (9000 g, 4 min) and 600 μl aliquots of the supernatant, filtered on 0.22-μm pore size Spin-X filter tubes (Costar), were centrifuged at 2-8°C (1400 g, 4 min) and 150 μl used for the assay of metanephrine by means of highpressure liquid chromatography with electrochemical detection, as described elsewhere [35] . S-COMT activity was expressed as the amount of metanephrine (in pmol) formed by the action of erythrocyte S-COMT upon epinephrine, per mg of haemoglobin in the sample, per h (pmol mg Hb
Bioanalysis of analytes
Determination of plasma concentrations of levodopa and 3-OMD was carried out in compliance with GLP at Nuvisan GmbH (Neu-Ulm, Germany) by liquid chromatography with electrochemical detection using a validated method with a lower limit of quantification (LLOQ) of 25 ng ml -1 .
The assay accuracy was 91.0-102.5%; the precision (%CV) was <7.3%. Determination of plasma concentrations of OPC in Study 1 was carried out in compliance with GLP at Algorithme Table 2 Summary of demographic data Analyses PD analysis. The following PD parameters were derived from the individual S-COMT activity profiles: maximum inhibition of COMT activity post dose (E max ), time to E max (t Emax ), and area under the effect-time curve (AUEC). The value observed before the first dose was taken as the baseline value (E 0 ). Descriptive statistics were prepared for each parameter. E max and AUEC were compared between treatment groups using a one-way analysis of variance with treatment as fixed effect. Point estimates of the arithmetic Opicapone effect on levodopa PK mean ratios and corresponding 90% confidence intervals (CIs) for each parameter and for the ratios OPC/placebo were presented and compared to 80-125% reference interval. This reference interval (bioequivalence testing) is extensively used as standard tests for bioequivalence between treatment arms, but can also be considered for other related endpoints. In this study, it was decided to test COMT inhibition in the same bioequivalence test as performed for PK to allow a comparison between OPC plasma exposure and COMT inhibition.
PK analysis. The PK parameters were derived, where appropriate, from the individual plasma concentration-time profiles of each analyte and included the maximum observed plasma concentration (C max ), time at which C max was observed (t max ), area under the plasma concentrationtime curve (AUC) calculated using the trapezoidal method from zero to the last quantifiable drug concentration (AUC 0-t ) and from zero to infinity (AUC 0-∞ ), elimination rate constant (λ z ) and the apparent terminal half-life (t ½ ). Summary statistics were prepared for each parameter. For levodopa and 3-OMD in plasma, C max and AUC were compared between treatment groups using ANOVA with treatment as fixed effect. Point estimates of the geometric mean ratios and the corresponding 90%CIs for each parameter and for the ratios OPC/placebo were obtained and compared to the 80-125% reference interval.
AEs. AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA, version 12.0). For the 
Results
Populations
In Study 1, a total of 52 subjects (25 male and 27 female) were enrolled and 48 subjects completed the study. Subjects with a mean age (range) of 34 (25-45) (Table 2 ). Four subjects were withdrawn from study participation. One subject was discontinued by the Principal Investigator due to an AE (darker skin below eyes followed by photosensitivity). Two subjects withdrew consent due to personal reasons. One subject was discontinued by the Principal Investigator due to a protocol violation (took penicillin due to an AE [tonsillitis] prescribed by the Principal Investigator). Therefore, all 52 subjects enrolled constituted the safety population set and the 48 subjects who completed the study constituted the PK population set. In Study 2, a total of 74 subjects (36 male and 38 female) were enrolled and 72 completed the study. The mean age (range) was 31 (Table 2) . One subject (5 mg OPC group, on Day 4) withdrew consent due to personal reasons and another (15 mg OPC group, on Day 16) was withdrawn due to an AE (joint sprain) and both were replaced. Therefore, all 74 subjects enrolled constituted the safety population set and the 72 subjects who completed the study constituted the PK population set. Table 3 displays the PD parameters of S-COMT. Statistical comparisons of OPC in relation to placebo group are also provided in Table 3 . In both studies, a sustained inhibitory effect of OPC upon S-COMT activity was observed throughout the entire studies ( Figure 1A and Figure 1D , for Study 1 and 2, respectively). The S-COMT activity over time on each LC and LB dosing day are depicted, respectively, in Figures 1B and  1C for Study 1, and in Figures 1E and 1F for Study 2. The sustained and dose-dependent inhibitory effect of OPC upon S-COMT activity is also observed on each LC and LB dosing day but in Study 2 ( Figures 1E and 1F ) an additional effect is perceived after 12 h postlevodopa dose but this effect is due to the daily administration of OPC, which happened 12 h after each LC and LB dose. Maximum S-COMT inhibition (E max ) was between 2.2 h (30 mg OPC, Study 1) and 13.4 h (15 mg OPC, Study 2) post-OPC dose (t Emax ), and ranged from 55% (5 mg OPC, Study 1) to 98% (50 mg OPC, Study 2; Table 3 ). All OPC treatments significantly inhibited, in a dose-dependent manner, both peak (as assessed by E max ) and extent (as assessed by AUEC) of S-COMT activity in relation to placebo (Table 3 ).
PD
PK
OPC. Table 4 presents the main PK parameters of plasma OPC. PK results for OPC were consistent with those obtained in previous studies [23, 24] . In Study 2, as blood samples were collected in relation to LC/LB administrations, last OPC administration was 12 h before each LC/LB administrations and due to its very short half-life, limited plasma data was available for OPC. Therefore, no PK parameters were calculated for Study 2. Table 4 Mean (coefficient of variation, %) plasma pharmacokinetic parameters of opicapone (OPC), on Days 21 and 28, following once-daily oral administrations of OPC (5, 15 and 30 mg) or placebo in Study 1 C max , maximum observed plasma concentration; t max , time taken to reach C max (t max values are median with range values in parentheses); t 1/2 , terminal plasma half-life; AUC 0-t , area under the concentration-time curve (AUC) from prior to each LC/LB dose to the last sampling time at which concentrations were at or above the limit of quantification; AUC 0-∞ , AUC from prior to each LC/LB dose to infinity; NA, not available; NC, not calculated
Opicapone effect on levodopa PK BIA 9-1103. In Study 1, there was no plasma determination of BIA 9-1103. Therefore, no PK parameters were calculated for BIA 9-1103 in Study 1. Systemic exposure to BIA 9-1103 in Study 2 increased in a dose-dependent manner and, apparently, by visual inspection, the steady-state is reached by Day 18. PK results for BIA 9-1103 were consistent with those obtained in a previous study [24] .
Levodopa. The plasma levodopa concentration-time profiles on each LC and LB dosing day are depicted, respectively, in Figures 2A and 2B for Study 1, and in Figures 2C and 2D for Study 2. Table 5 presents the main PK parameters of plasma levodopa. Statistical comparisons of OPC in relation to control group (placebo) are also provided in Table 5 . The levodopa C max was usually similar following OPC when compared to placebo, namely when considering the known variability of levodopa absorption [36] . All OPC treatments, in relation to the placebo group, presented a higher extent of exposure (AUC) to levodopa following either LC or LB doses (Table 5) . A relevant increase, although not dose-dependent in Study 1, in the levodopa AUC occurred with all OPC dose groups in relation to placebo. This is in line with the observed increase of up to 2 h of the levodopa t 1/2 with OPC when compared to the placebo group. Of note, plasma levodopa C max and AUC were considerably higher after LB compared with LC in both studies (Table 5) .
3-OMD.
The plasma 3-OMD concentration-time profiles on each LC and LB dosing day are depicted, respectively, in Figures 3A and 3B for Study 1, and in Figures 3C and 3D for Study 2. Table 6 presents the main PK parameters of plasma 3-OMD. Statistical comparisons of OPC in relation to control group (placebo) are also provided in Table 6 . All OPC treatments, in relation to the placebo group, resulted in marked decreases in the extent of exposure (AUC) to 3-OMD following either LC or LB doses (Table 6) . Furthermore, OPC decreased 3-OMD C max and AUC in a dose-dependent manner.
Tolerability
The tolerability profile of all treatments in both studies was favourable. Overall, in Study 1, a total of 135 treatment emergent (TEAEs) were reported by 40 (76.9%) subjects with no dose-effect relationship. The majority of TEAEs were of mild intensity. Majority (111) of TEAEs were considered at least possibly related to the study products. Among these 111 TEAEs, following the treatment groups of placebo, 5, 15 mg . Four subjects were withdrawn from study participation. One subject was discontinued (Day 17 of the 15 mg OPC group) by the Principal Investigator due to an AE (darker skin below the eyes followed by photosensitivity), which was considered possibly related to treatment. Two subjects withdrew their consent due to personal reasons. One subject was discontinued (Day 17 of the placebo group) by the Principal Investigator due to a protocol violation (took penicillin due to an AE [tonsillitis] prescribed by the Principal Investigator). One subject presented a clinical significant increase in plasma potassium levels at the follow-up visit. This potassium increase, which was considered possibly related to treatment by the investigator, was resolved without any sequelae. This subject already presented a clinically relevant abnormal plasma potassium levels at screening; a subsquent test was performed 5 days after and the result was normal (4.7 mEq l -1 ). One subject presented clinically relevant aspartate aminotransferase and alanine aminotransferase levels (175 and 135 IU l -1 , respectively) at discharge of the treatment period. These increases, which were considered possibly related to treatment by the investigator, were resolved without any sequelae at the follow-up visit. There were no serious AEs or deaths during this study. Neither trends nor relevant changes from baseline were observed in vital signs or ECG parameters. In Study 2, a total of 44 AEs were reported by 29 (39.2%) subjects. Among these, 41 AEs were considered treatment emergent (TEAEs) with no dose-effect relationship. The majority of TEAEs were of mild intensity. Twenty-four (24) TEAEs were considered at least possibly related to the study products. Among these 41 TEAEs, the most common were headaches (eight TEAEs reported by eight subjects), nauseas (five TEAEs by five subjects), back pains (two TEAEs by two subjects) and diarrhoea (two TEAEs by two subjects). Twenty-four TEAEs were considered at least possibly related to study drug: four in the placebo group (one palpitation, one disturbance in attention, one blepharospasm and 1 headache), eight in 5 mg OPC (two diarrhoeas, one vomiting, four headaches and one somnolence), five in 15 mg OPC (four nauseas and one paraesthesia), and seven in 50 mg OPC (one asthenia, one headache, one insomnia, one nausea, one dizziness, one pruritus and one orthostatic hypotension). One subject (5 mg OPC group, on Day 4) withdrew the consent due to personal reasons and another (15 mg OPC group, on Day 16) was withdrawn due to an AE (joint sprain). There was one serious AE (facial paralysis), which occurred 4 days after last investigational medicinal product 
Discussion
The purpose of these studies was to compare the effect of OPC vs. placebo upon COMT activity and the PK profiles of a single oral dose of LC or LB following either a once-daily OPC morning or evening regimen apart at least 1 h from levodopa therapy. In both studies, the extent of systemic exposure to levodopa, as measured by AUC, in subjects who received OPC was considerably greater than that in placebo-treated individuals. In Study 1, the increase in levodopa AUC was significant for both LC and LB at all OPC doses, and significant for LC at all OPC doses but only at both OPC 15 and 50 mg for LB in Study 2. Moreover, this increase it was not dose related in Study 1, and this apparent lack of correlation between dose level of OPC and the increase in levodopa AUC has been previously observed in our studies (data on file). This interaction was also reported for other COMT inhibitors and explanations that have been considered include degradation of levodopa by other metabolic pathways, while inhibition of COMT becomes more marked [37] , and/or competition between the COMT inhibitors and levodopa for the saturable transport of large neutral amino acids at the proximal small intestine level [38] [39] [40] . Worth mentioning is that, plasma levodopa C max and AUC were considerably higher after LC compared with LC in both studies. This finding has been previously observed in our studies (data on file) and recently reported by others [41] .
When compared to placebo, OPC increases the levodopa extent of exposure (AUC), accompanied by a prolonged half-life (t 1/2 ), which is believed to be associated with its pronounced, long-lasting and sustained COMT inhibition. Peak (E max ) and extent (AUEC) of S-COMT inhibition with OPC followed a dose-dependent manner, although this was not entirely proportional to the dose administered. These observations fit well with the findings on the dosedependent effects upon 3-OMD availability and exposure. In fact, the formation of 3-OMD from levodopa is dependent on the COMT activity, particularly at the intestinal level, the main site of O-methylation of levodopa.
As previously reported, dose-proportionality in C max and AUC ∞ was observed for OPC [23, 24] . OPC shows a long duration of COMT inhibition in human erythrocytes. Despite the low plasma exposure and short clearance half-life of the inhibitor, the levels of erythrocyte COMT inhibition are sustained far beyond the observable point of clearance of circulating drug, which is due to the long residence time of the reversible COMT-OPC complex [23, 24] .
The tolerability profile was favourable and similar between placebo and OPC. Studies in healthy subjects with concomitant administrations of OPC and levodopa/AADCi (either carbidopa or benserazide) demonstrated that OPC was well tolerated, inhibited the COMT in a potent manner, but showed a certain degree of interaction during the absorption phase between levodopa/AADCi and OPC (data on file). On the basis of the results obtained in these studies, evening OPC regimens, potentially a once-daily bedtime administration 1 h after the last daily levodopa/AADCi, are considered to provide higher flexibility to the daily levodopa adjustment by enhancing levodopa's optimization and avoiding any interaction during the levodopa absorption phase. This interaction between levodopa/AADCi and OPC during the absorption phase was in fact found to be minimized when both administrations were separated by 1 h; this is also supported by evidence on the PK characteristics observed for levodopa and OPC, namely the half-life of the former (~1.5 h) and the t max for the latter (1.5-4.0 h).
In conclusion, OPC, as once-daily oral evening regimen and 1 h apart from levodopa therapy, increases the bioavailability of levodopa associated with its pronounced, longlasting and sustained COMT inhibition.
